{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:16:25Z","timestamp":1789614985166,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009187","name":"MRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","award":["553191.D-OTH.178973"],"award-info":[{"award-number":["553191.D-OTH.178973"]}],"id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jhepr.2025.101382","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T19:35:36Z","timestamp":1740771336000},"page":"101382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFN\u03b1 non-response"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4210-2411","authenticated-orcid":false,"given":"Douglas L.","family":"Fink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2807-6272","authenticated-orcid":false,"given":"David","family":"Etoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2747-3997","authenticated-orcid":false,"given":"Robert","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1018-7150","authenticated-orcid":false,"given":"Orest","family":"Idilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Kartikapallil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8055-1927","authenticated-orcid":false,"given":"Olivia","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6827-3190","authenticated-orcid":false,"given":"Hannah F.","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.F.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6384-1462","authenticated-orcid":false,"given":"Mala K.","family":"Maini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6146-9708","authenticated-orcid":false,"given":"Upkar S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101382_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: a lancet gastroenterology & hepatology commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101382_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/cid\/ciad506","article-title":"Chronic hepatitis B finite treatment: similar and different concerns with new drug classes","volume":"78","author":"Peters","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jhepr.2025.101382_bib3","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41575-019-0196-9","article-title":"Restoring, releasing or replacing adaptive immunity in chronic hepatitis B","volume":"16","author":"Maini","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101382_bib4","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jhep.2016.01.028","article-title":"The role of innate immunity in the immunopathology and treatment of HBV infection","volume":"64","author":"Maini","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2025.101382_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhepr.2025.101382_bib6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ni.3212","article-title":"Guarding the frontiers: the biology of type III interferons","volume":"16","author":"Wack","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhepr.2025.101382_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2009.06.054","article-title":"Temporal analysis of early immune responses in patients with acute hepatitis B virus infection","volume":"137","author":"Dunn","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2025.101382_bib8","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.25730","article-title":"Transcriptomic analysis of the woodchuck model of chronic hepatitis B","volume":"56","author":"Fletcher","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101382_bib9","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1128\/JVI.01844-08","article-title":"Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections","volume":"83","author":"Stacey","year":"2009","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jhepr.2025.101382_bib10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1089\/jir.2013.0068","article-title":"Endogenous IFN\u03bb in viral hepatitis patients","volume":"34","author":"De Groen","year":"2014","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.jhepr.2025.101382_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2022.02.016","article-title":"Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection","volume":"77","author":"Montanari","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2025.101382_bib12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2024.02.017","article-title":"Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity","volume":"81","author":"Narmada","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2025.101382_bib13","article-title":"Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection","volume":"4","author":"van Buuren","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101382_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.virol.2010.02.022","article-title":"Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in\u00a0vivo activities","volume":"401","author":"Pagliaccetti","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.jhepr.2025.101382_bib15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.1300252","article-title":"IL-27, a cytokine, and IFN-\u03bb1, a type III IFN, are coordinated to regulate virus replication through type I IFN","volume":"192","author":"Cao","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jhepr.2025.101382_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/imr.13304","article-title":"Human autoantibodies neutralizing type I IFNs: from 1981 to 2023","volume":"322","author":"Bastard","year":"2024","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jhepr.2025.101382_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and hepatitis B: current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2025.101382_bib18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3851\/IMP2711","article-title":"Presence of anti-interferon antibodies is not associated with non-response to pegylated interferon treatment in chronic hepatitis B","volume":"19","author":"Arends","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhepr.2025.101382_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.01611","article-title":"When hepatitis B virus meets interferons","volume":"9","author":"Tan","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jhepr.2025.101382_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2025.101382_bib21","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial","volume":"77","author":"Etzion","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101382_bib22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2025.101382_bib23","article-title":"Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFN\u03b1 and B cell subsets","volume":"4","author":"Bradford","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhepr.2025.101382_bib24","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"issue":"7","key":"10.1016\/j.jhepr.2025.101382_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-024-01761-2","article-title":"Prevalence of anti-interferon-alpha auto-antibodies in patients with antibody deficiency","volume":"44","author":"Fink","year":"2024","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.jhepr.2025.101382_bib26","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jhepr.2025.101382_bib27","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jhepr.2025.101382_bib28","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/jir.2023.0003","article-title":"Autoantibodies neutralizing type III interferons are uncommon in patients with severe coronavirus disease 2019 pneumonia","volume":"43","author":"Vanker","year":"2023","journal-title":"J\u00a0Interferon Cytokine Res"},{"issue":"8","key":"10.1016\/j.jhepr.2025.101382_bib29","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41551-022-00925-y","article-title":"Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries","volume":"6","author":"Credle","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.jhepr.2025.101382_bib30","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in \u223c4% of uninfected individuals over 70 years old and account for \u223c20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jhepr.2025.101382_bib31","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20212126","article-title":"Pathogenic autoantibodies to IFN-\u03b3 act through the impedance of receptor assembly and Fc-mediated response","volume":"219","author":"Shih","year":"2022","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jhepr.2025.101382_bib32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.20061287","article-title":"Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage","volume":"204","author":"Dunn","year":"2007","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jhepr.2025.101382_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-023-01371-w","article-title":"Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.jhepr.2025.101382_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","article-title":"Age-associated B cells","volume":"38","author":"Cancro","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jhepr.2025.101382_bib35","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J\u00a0Clin Invest"}],"updated-by":[{"DOI":"10.1016\/j.jhepr.2025.101520","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000}}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592500059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592500059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:23:43Z","timestamp":1746415423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258955592500059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S258955592500059X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101382","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.24.614789","asserted-by":"object"}]},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Auto-antibodies against interferons are common in people living with chronic hepatitis B virus infection and associate with PegIFN\u03b1 non-response","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101382"}}